CL · Colgate Palmolive Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.38B | $20.10B | $19.46B | $17.97B | $17.42B | $16.47B |
| Cost of Revenue | $8.13B | $7.94B | $8.13B | $7.72B | $7.05B | $6.45B |
| Gross Profit | $12.25B | $12.16B | $11.33B | $10.25B | $10.38B | $10.02B |
| R&D | $366.00M | $355.00M | $343.00M | $320.00M | $307.00M | $290.00M |
| SG&A | $7.90B | $7.73B | $7.15B | $6.57B | $6.41B | $6.02B |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $630.00M | $605.00M | $567.00M | $545.00M | $556.00M | $539.00M |
| Operating Income | $3.31B | $4.27B | $3.98B | $2.89B | $3.33B | $3.88B |
| Interest Expense | $267.00M | $292.00M | $299.00M | $172.00M | $195.00M | $184.00M |
| Income Tax | $798.00M | $907.00M | $937.00M | $693.00M | $749.00M | $787.00M |
| Net Income | $2.13B | $2.89B | $2.30B | $1.78B | $2.17B | $2.69B |
| EPS - Basic | $2.64 | $3.53 | $2.78 | $2.13 | $2.56 | $3.15 |
| EPS - Diluted | $2.63 | $3.51 | $2.77 | $2.13 | $2.55 | $3.14 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.29B | $1.10B | $966.00M | $775.00M | $832.00M | $888.00M |
| Accounts Receivable | $1.68B | $1.52B | $1.59B | $1.50B | $1.30B | $1.26B |
| Inventory | $2.03B | $1.99B | $1.93B | $2.07B | $1.69B | $1.67B |
| Accounts Payable | $2.09B | $1.80B | $1.70B | $1.55B | $1.48B | $1.39B |
| Current Assets | $5.71B | $5.32B | $5.28B | $5.11B | $4.40B | $4.34B |
| Total Assets | $16.33B | $16.05B | $16.39B | $15.73B | $15.04B | $15.92B |
| Current Liabilities | $6.85B | $5.76B | $4.74B | $4.00B | $4.05B | $4.40B |
| Long-term Debt | $6.87B | $7.29B | $8.22B | $8.74B | $7.19B | $7.33B |
| Total Liabilities | $15.96B | $15.50B | $15.44B | $14.93B | $14.07B | $14.82B |
| Stockholders' Equity | $54.00M | $212.00M | $609.00M | $401.00M | $609.00M | $743.00M |
| Retained Earnings | $26.59B | $26.14B | $25.29B | $24.57B | $24.35B | $23.70B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.20B | $4.11B | $3.75B | $2.56B | $3.33B | $3.72B |
| Investing Cash Flow | ($817.00M) | ($534.00M) | ($742.00M) | ($1.60B) | ($592.00M) | ($779.00M) |
| Financing Cash Flow | ($3.26B) | ($3.39B) | ($2.79B) | ($952.00M) | ($2.77B) | ($2.92B) |
| CapEx | $564.00M | $561.00M | $705.00M | $696.00M | $567.00M | $409.00M |
| Free Cash Flow | $3.63B | $3.55B | $3.04B | $1.86B | $2.76B | $3.31B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 60.1% | 60.5% | 58.2% | 57.0% | 59.6% | 60.8% |
| Operating margin | 16.2% | 21.2% | 20.5% | 16.1% | 19.1% | 23.6% |
| EBITDA margin | 19.3% | 24.2% | 23.4% | 19.1% | 22.3% | 26.9% |
| Net margin | 10.5% | 14.4% | 11.8% | 9.9% | 12.4% | 16.4% |
| Free cash flow margin | 17.8% | 17.6% | 15.6% | 10.4% | 15.8% | 20.1% |
| FCF / Net income | 1.70 | 1.23 | 1.32 | 1.04 | 1.27 | 1.23 |
| R&D / Revenue | 1.8% | 1.8% | 1.8% | 1.8% | 1.8% | 1.8% |
| SG&A / Revenue | 38.8% | 38.5% | 36.8% | 36.5% | 36.8% | 36.5% |
| Effective tax rate | 27.2% | 23.9% | 28.9% | 28.0% | 25.7% | 22.6% |
| Return on assets | 13.1% | 18.0% | 14.0% | 11.3% | 14.4% | 16.9% |
| Return on equity | 3948.1% | 1362.7% | 377.7% | 445.1% | 355.7% | 362.7% |
| Return on invested capital | 34.7% | 43.3% | 32.1% | 22.8% | 31.7% | 37.2% |
| Liquidity | ||||||
| Current ratio | 0.83 | 0.92 | 1.11 | 1.28 | 1.09 | 0.99 |
| Quick ratio | 0.54 | 0.58 | 0.71 | 0.76 | 0.67 | 0.61 |
| Cash ratio | 0.19 | 0.19 | 0.20 | 0.19 | 0.21 | 0.20 |
| Leverage | ||||||
| Debt / Equity | 127.24 | 34.38 | 13.50 | 21.80 | 11.81 | 9.87 |
| Debt / Assets | 0.42 | 0.45 | 0.50 | 0.56 | 0.48 | 0.46 |
| Debt / EBITDA | 1.75 | 1.50 | 1.81 | 2.54 | 1.85 | 1.66 |
| Interest coverage | 12.4x | 14.6x | 13.3x | 16.8x | 17.1x | 21.1x |
| Equity multiplier | 302.41 | 75.69 | 26.92 | 39.23 | 24.70 | 21.43 |
| Liabilities / Assets | 0.98 | 0.97 | 0.94 | 0.95 | 0.94 | 0.93 |
| Efficiency | ||||||
| Asset turnover | 1.25 | 1.25 | 1.19 | 1.14 | 1.16 | 1.03 |
| Inventory turnover | 4.00 | 4.00 | 4.20 | 3.72 | 4.16 | 3.86 |
| Days sales outstanding | 30d | 28d | 30d | 31d | 27d | 28d |
| Days inventory outstanding | 91d | 91d | 87d | 98d | 88d | 95d |
| Days payable outstanding | 94d | 83d | 76d | 73d | 77d | 79d |
| Cash conversion cycle | 27d | 36d | 40d | 55d | 38d | 44d |
| Valuation | ||||||
| P / E | 30.0x | 25.9x | 28.8x | 37.0x | 33.5x | 27.2x |
| P / B | 1186.9x | 353.0x | 108.5x | 164.8x | 118.9x | 98.9x |
| P / S | 3.1x | 3.7x | 3.4x | 3.7x | 4.2x | 4.5x |
| EV / EBITDA | 17.7x | 16.6x | 16.1x | 21.5x | 20.3x | 18.1x |
| Growth | ||||||
| Revenue growth (YoY) | 1.4% | 3.3% | 8.3% | 3.1% | 5.8% | 5.0% |
| Revenue CAGR (3y) | 4.3% | 4.9% | 5.7% | 4.6% | 4.7% | 2.1% |
| Revenue CAGR (5y) | 4.4% | 5.1% | 5.1% | 3.1% | 2.8% | 0.5% |
| Gross profit growth (YoY) | 0.7% | 7.4% | 10.5% | -1.2% | 3.6% | 7.4% |
| Operating income growth (YoY) | -22.5% | 7.1% | 37.7% | -13.2% | -14.2% | 9.3% |
| Net income growth (YoY) | -26.2% | 25.6% | 28.9% | -17.6% | -19.6% | 13.9% |
| EPS growth (YoY) | -25.1% | 26.7% | 30.0% | -16.5% | -18.8% | 14.2% |
| EPS CAGR (3y) | 7.3% | 11.2% | -4.1% | -8.2% | -2.5% | 11.3% |
| EPS CAGR (5y) | -3.5% | 5.0% | 0.1% | -1.4% | -1.3% | 15.6% |
| FCF growth (YoY) | 2.5% | 16.6% | 63.4% | -32.6% | -16.7% | 18.3% |
| FCF CAGR (5y) | 1.9% | 4.9% | 3.0% | -5.8% | 1.6% | 7.9% |
| Book value growth (YoY) | -74.5% | -65.2% | 51.9% | -34.2% | -18.0% | 535.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$20.38B totalOral Personal And Home Care$15.77B · 77.4%
Pet Nutrition$4.61B · 22.6%
Geographic
$19.36B totalLatin America$4.78B · 24.7%
North America$4.04B · 20.9%
US$3.60B · 18.6%
Europe$2.96B · 15.3%
Asia Pacific$2.81B · 14.5%
Africa Eurasia$1.17B · 6.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.21
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations
Comparing COLGATE PALMOLIVE CO against the 5 most active filers in the same SIC group.
Dividends
$2.09/share trailing 12 months · +3.5% YoY
| Ex-date | Per share |
|---|---|
| Apr 20, 2026 | $0.5300 |
| Jan 21, 2026 | $0.5200 |
| Oct 17, 2025 | $0.5200 |
| Jul 18, 2025 | $0.5200 |
| Apr 17, 2025 | $0.5200 |
| Jan 21, 2025 | $0.5000 |
| Oct 18, 2024 | $0.5000 |
| Jul 19, 2024 | $0.5000 |
| Apr 19, 2024 | $0.5000 |
| Jan 19, 2024 | $0.4800 |
| Oct 20, 2023 | $0.4800 |
| Jul 20, 2023 | $0.4800 |
| Apr 20, 2023 | $0.4800 |
| Jan 20, 2023 | $0.4700 |
| Oct 20, 2022 | $0.4700 |
| Jul 20, 2022 | $0.4700 |
| Apr 20, 2022 | $0.4700 |
| Jan 21, 2022 | $0.4500 |
| Oct 20, 2021 | $0.4500 |
| Jul 20, 2021 | $0.4500 |
| Apr 20, 2021 | $0.4500 |
| Jan 22, 2021 | $0.4400 |
| Oct 22, 2020 | $0.4400 |
| Jul 17, 2020 | $0.4400 |